sever
fever
thrombocytopenia
syndrom
sft
emerg
tickborn
diseas
caus
sft
viru
sftsv
infect
despit
gradual
increas
sft
case
high
mortal
endem
region
specif
viral
therapi
vaccin
avail
develop
singl
recombin
plasmid
dna
encod
sftsv
gene
gn
gc
togeth
npn
fusion
antigen
vaccin
candid
viral
antigen
fuse
like
tyrosin
ligand
gene
incorpor
plasmid
enhanc
cellmedi
immun
vaccin
dna
provid
complet
protect
ifnar
ko
mice
upon
lethal
sftsv
challeng
wherea
immun
plasmid
without
gene
result
partial
protect
sinc
fail
detect
antibodi
surfac
glycoprotein
gn
gc
immun
mice
antigenspecif
cellular
immun
confirm
enhanc
antigenspecif
cell
respons
might
play
major
role
protect
final
evalu
degre
protect
immun
provid
protein
immun
individu
glycoprotein
gn
gc
although
protein
antigen
induc
signific
level
neutral
activ
sftsv
gn
vaccin
result
rel
higher
neutral
activ
better
protect
gc
vaccin
howev
antigen
fail
provid
complet
protect
given
dna
vaccin
fail
induc
suffici
immunogen
human
trial
compar
protein
vaccin
optim
combin
dna
protein
element
proper
select
target
antigen
incorpor
effici
adjuv
need
investig
sftsv
vaccin
develop
sever
fever
thrombocytopenia
syndrom
sft
emerg
tickborn
infect
endem
east
asia
includ
china
korea
japan
gradual
rise
diseas
incid
rel
high
mortal
becom
seriou
public
health
problem
endem
countri
studi
develop
recombin
plasmid
dna
encod
four
antigen
gn
gc
np
ns
sft
viru
sftsv
vaccin
candid
order
enhanc
mediat
immun
viral
antigen
fuse
gene
incorpor
plasmid
immun
dna
vaccin
provid
complet
protect
lethal
sftsv
infect
ifnar
ko
mice
antigenspecif
cell
respons
might
play
major
role
protect
sinc
observ
enhanc
cell
respons
specif
viral
antigen
fail
detect
neutral
antibodi
immun
mice
immun
either
viral
glycoprotein
gn
protein
induc
rel
higher
neutral
activ
better
protect
sftsv
infect
gc
antigen
neither
gener
complet
protect
therefor
optim
combin
dna
protein
element
well
proper
select
target
antigen
might
requir
produc
effect
sftsv
vaccin
ccbi
leukocytopenia
thrombocytopenia
diseas
mortal
sft
patient
estim
even
though
major
sft
case
report
china
korea
japan
sftsv
infect
southern
asia
includ
vietnam
recent
report
retrospect
survey
current
specif
viral
therapi
vaccin
avail
effect
vaccin
need
combat
rel
high
mortal
especi
elderli
patient
spread
sftsv
human
vaccin
develop
sft
earli
discoveri
phase
studi
vaccin
candid
use
anim
infect
model
immun
ns
antigen
freund
adjuv
mice
natur
resist
sftsv
partial
mimic
human
infect
fail
enhanc
viral
clearanc
although
induc
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
attenu
recombin
vesicular
stomat
viru
rvsv
vaccin
express
sftsv
gngc
glycoprotein
elicit
high
titer
protect
neutral
antibodi
wild
type
interferon
receptor
knockout
ifnar
ko
mice
clearli
show
singl
dose
rvsv
carri
sftsv
gngc
could
provid
complet
protect
lethal
challeng
sftsv
young
old
ifnar
ko
mice
promis
infect
model
sever
human
infect
sftsv
nevertheless
potenti
role
cellular
immun
viral
antigen
complet
protect
examin
studi
although
adopt
transfer
immun
sera
mice
immun
rvsvgngc
ifnar
ko
mice
provid
partial
protect
lethal
sftsv
challeng
studi
develop
recombin
plasmid
dna
psftsv
encod
extracellular
domain
gn
gc
npn
fusion
antigen
dna
vaccin
candid
examin
whether
could
provid
protect
immun
lethal
sftsv
infect
ifnar
ko
mice
order
facilit
process
present
sftsv
antigen
dendrit
cell
dc
enhanc
antigenspecif
cell
respons
recombin
antigen
fuse
fmslike
tyrosin
ligand
moreov
gener
recombin
dna
encod
addit
recombin
viral
antigen
enhanc
cellmedi
immun
vaccin
provid
complet
protect
ifnar
ko
mice
upon
lethal
sftsv
challeng
wherea
immun
psftsv
elicit
partial
protect
indic
antigenspecif
cellular
immun
respons
enhanc
coexpress
could
play
signific
role
protect
lethal
sftsv
infect
confirm
significantli
higher
level
gn
npspecif
cell
respons
mice
vaccin
compar
mock
vectorimmun
mice
therefor
result
indic
enhanc
antigenspecif
cell
immun
multipl
sftv
order
gener
plasmid
dna
vaccin
gene
encod
ectodomain
gn
gc
genebank
access
npn
fusion
protein
genebank
access
respect
synthes
genscript
piscataway
nj
usa
clone
vector
genexin
seongnam
republ
korea
gene
fuse
signal
peptid
tissu
plasminogen
activ
tpa
uniport
uniport
nterminu
psftsv
fig
addit
murin
gene
uniport
also
synthes
genscript
clone
psftsv
fig
confirm
express
clone
gene
psftsv
hek
cell
overexpress
recombin
protein
supernat
purifi
akta
start
affin
confirm
elisa
immunoblot
analysi
fig
viral
antigen
detect
cell
cultur
supernat
well
cellular
lysat
fig
ko
mice
korean
sftsv
isol
examin
inocul
mice
x
x
ffu
fig
upon
infect
mice
gradual
lost
bodi
weight
becam
moribund
third
fifth
day
infect
depend
infect
dose
infect
mice
die
infect
fig
similar
surviv
kinet
previous
report
ifnar
ko
mice
infect
sftsv
strain
indic
korean
sftsv
isol
possess
equival
degre
virul
prior
chines
isol
platelet
count
mice
infect
x
ffu
sftsv
significantli
declin
infect
mean
platelet
volum
infect
mice
significantli
higher
control
anim
fig
b
suggest
platelet
destruct
activ
platelet
product
simultan
occur
lethal
infect
assess
protect
efficaci
dna
vaccin
group
mice
immun
ccbi
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mock
vector
psftsv
three
time
subcutan
challeng
lethal
dose
ffumous
sftsv
fig
mockimmun
mice
expir
sftsv
infect
contrast
mice
immun
protect
lethal
viral
challeng
mice
vaccin
psftsv
surviv
fig
consist
anim
lost
weight
vaccin
mice
mean
sd
approxim
five
fifti
time
lower
psftsvvaccin
mice
mean
sd
vectorimmun
mice
mean
sd
respect
given
immun
gnfc
gcfc
protein
induc
specif
antibodi
ifnar
ko
mice
fig
significantli
enhanc
cell
respons
fuse
target
antigen
promot
persist
mainten
antigenspecif
cell
vivo
studi
also
observ
signific
enhanc
gn
npspecif
cell
respons
well
cell
presenc
express
fig
c
correl
